Previous Article | Next Article 
Journal of Virology, September 2008, p. 8887-8890, Vol. 82, No. 17
0022-538X/08/$08.00+0 doi:10.1128/JVI.00415-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion Peptide
Berend Jan Bosch,
Willem Bartelink, and
Peter J. M. Rottier*
Virology Division, Department of Infectious Diseases and Immunology, Utrecht University, Faculty of Veterinary Medicine, and Institute of Biomembranes, Yalelaan 1, 3584 CL Utrecht, The Netherlands
Received 26 February 2008/
Accepted 9 June 2008

ABSTRACT
Unlike other class I viral fusion proteins, spike proteins on
severe acute respiratory sydrome coronavirus virions are uncleaved.
As we and others have demonstrated, infection by this virus
depends on cathepsin proteases present in endosomal compartments
of the target cell, suggesting that the spike protein acquires
its fusion competence by cleavage during cell entry rather than
during virion biogenesis. Here we demonstrate that cathepsin
L indeed activates the membrane fusion function of the spike
protein. Moreover, cleavage was mapped to the same region where,
in coronaviruses carrying furin-activated spikes, the receptor
binding subunit of the protein is separated from the membrane-anchored
fusion subunit.

TEXT
The spike (S) protein of the enveloped coronaviruses (CoV) belongs
to the class I viral fusion proteins (
3), which, upon virion-cell
attachment, mediate virus entry through an extensive refolding
process that involves the formation of a coiled-coil structure
and results in the fusion of the viral and target cell membranes.
Crucial to the refolding process of class I fusion proteins
is the proteolytic activation of their fusogenic potential by
cellular, usually furin-like proteases, encountered during biogenesis
in the exocytic pathway. Proteolysis occurs N-proximal to the
fusion peptide (Fig.
1), allowing the projection of this peptide
toward the target cell membrane in a spring-loaded manner. The
S proteins of many CoV, such as that of murine hepatitis virus
strain A59 (MHV-A59) (
7), are cleaved by furin-like proteases,
generating a receptor binding unit (S1) and a C-terminal membrane-anchored
fusion unit (S2). However, in contrast to that of class I fusion
proteins, this cleavage occurs

200 residues upstream of the
predicted fusion peptide (
2,
5) (Fig.
1). Remarkably, in the
case of MHV-A59, this furin-mediated cleavage of the spikes
appeared not to be essential for virus entry (
7). Moreover,
in many CoV, including the CoV responsible for severe acute
respiratory syndrome (SARS), furin-mediated cleavage of the
spikes appeared not to occur (
17), leaving a conundrum as to
whether and how these proteins are proteolytically primed for
fusion. We and others recently demonstrated that SARS-CoV or
SARS-CoV spike protein-pseudotyped retroviruses utilize the
enzymatic activity of endosomal cathepsin L protease for viral
entry, suggesting the possibility of proteolytic activation
of the spike protein in the endosomal route during cell entry
rather than during cell exit (
10,
16). However, no actual cleavage
of the S protein by the cathepsin enzyme has been demonstrated
yet. In this note we examine whether, and at which position
in the SARS-CoV spike protein, cathepsin L proteolytically activates
the fusion function.
We first investigated whether the fusogenic potential of the
SARS-CoV spike protein could be activated by cathepsin L protease
in a cell-based system with recombinantly expressed SARS-CoV
spike. Vero cells were cotransfected with the pTSh vector containing
the human codon-optimized gene encoding the SARS-CoV spike (strain
BJ01; a kind gift of H. Deng [
13]) and the pEGFP-N1 vector (Clontech).
Twenty-four hours after transfection, cells were either mock
treated (phosphate-buffered saline [PBS]-Ca
2+/Mg
2+ [PBS+], pH
6.0) or treated with cathepsin L protease (2 µg/ml in
PBS+, pH 6.0; Calbiochem) for 20 min at 37°C, after which
the culture medium was replaced with Dulbecco's modified Eagle
medium. As a control we used
L-1-tosylamide-2-phenylethyl chloromethyl
ketone (TPCK)-treated trypsin (2 µg/ml in PBS+, pH 7.4;
Sigma), which has been shown to induce SARS-CoV spike-mediated
cell-cell fusion (
12,
17). Four hours later, cells were fixed,
and S protein expression was visualized using a polyclonal antiserum
against SARS-CoV S peptide (AZ1; residues 27 to 51; a kind gift
of L. A. Babiuk) by confocal laser scanning microscopy (Fig.
2A). Cell-cell fusion was detected in SARS-CoV spike protein-expressing
cells treated with cathepsin L protease at pH 6 by the presence
of multiple syncytia. Cytoplasmic content mixing among the fused
cells was evident by the occurrence of green fluorescent protein
(GFP) throughout the syncytia. The extent of syncytium formation
was semiquantified by counting the number of nuclei in the S
protein-expressing cells (63 cells) (Fig.
2B). Cell-cell fusion
was also elicited by trypsin proteolysis at neutral pH. Mock-treated
cells remained largely mononucleated, indicating that the cathepsin
L protease activity, not the slightly acidic buffer condition,
was responsible for the cell fusion. Apparently, cathepsin L
proteolysis activates the fusion potential of the spike protein.
To examine the proteolysis of the SARS-CoV spike protein by
the cathepsin L protease, we expressed the S ectodomain (SARS-Se;
residues 14 to 1193) in stably transfected
Drosophila S2 cell
lines (Invitrogen); the protein was flanked by an N-terminal
BiP signal sequence, a C-terminal GCN4 domain facilitating its
trimerization, and a Strep tag for affinity purification (IBA
GmbH). Likewise, we expressed the S protein ectodomain of another
human coronavirus, human coronavirus strain NL63 (HCoV-NL63)
(NL63-Se; residues 16 to 1294; constructed from pcDNA3.1-HCoV-NL63,
a kind gift of H. Choe [
10]). Like SARS-CoV, HCoV-NL63 uses
the ACE2 receptor for cell entry and carries uncleaved spikes
on its virions, but it is independent of cathepsin L activity
for its entry into cells (
10). SARS-Se and NL63-Se were purified
from the culture medium using Strep-Tactin affinity chromatography
(IBA GmbH) and gel filtration chromatography. Five micrograms
of each protein was incubated with either TPCK-trypsin (0, 50,
and 250 ng/ml in PBS [pH 7.4]) or cathepsin L protease (0, 0.4,
2, or 10 µg/ml in PBS [pH 5.5]) for 1 h at room temperature
and then analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Treatment of SARS-Se with cathepsin
L protease yielded two distinct fragments with apparent molecular
masses of 90 kDa and 70 kDa by SDS-PAGE, similar to the two
fragments observed after trypsin treatment (Fig.
3A) (
11). Cathepsin
L cleavage of SARS-Se was also observed at pH 5 and 6 but not
upon incubation at a neutral pH (pH 7.4) (data not shown), consistent
with the known acid preference of the enzyme's autoactivation
(
9,
18). NL63-Se was not cleaved by either cathepsin L or trypsin
(Fig.
3B), in accordance with the independence of HCoV-NL63
of cathepsin L protease activity during cell entry, which we
observed previously (
10).
The identities of the two proteolytic SARS-CoV spike fragments
were investigated by Western blot analysis using two polyclonal
anti-peptide sera specific to sequences within the N-terminal
(AZ1; residues 27 to 51) or C-terminal (AZ4; residues 1122 to
1142; a kind gift of L. A. Babiuk) part of the SARS-CoV spike
protein. The results confirmed that the 90-kDa and 70-kDa polypeptides
correspond to the S1 and S2 domains, respectively (Fig.
3C and D).
To precisely map the cathepsin L cleavage site, the proteolytic
fragments were electroblotted onto a Sequiblot polyvinylidene
difluoride membrane (Bio-Rad) and stained with GelCode Blue
(Pierce), and the 70 kDa polypeptide was excised and subjected
to N-terminal sequencing using Edman degradation (Cambridge
Peptides Ltd.). Interestingly, the cathepsin L cleavage site
was found to map to the region of the S protein where in other
coronavirus S proteins the furin cleavage site occurs (Fig.
4). Processing of the SARS-CoV S protein by cathepsin L hence
gives rise to the characteristic S1 and S2 domains The location
of the cathepsin cleavage site was mapped 11 residues downstream
of a previously identified trypsin cleavage site (
11), consistent
with the similar sizes of the products obtained with the two
enzymes (Fig.
3).
Our observations demonstrate for the first time directly that
cathepsin L cleavage activates the SARS-CoV spike protein for
membrane fusion. They also demonstrate that this cleavage does
not occur at or near the putative fusion peptide but in an apparently
exposed protein domain some 200 residues upstream, with no such
hydrophobic peptide in the immediate vicinity. Hence, our results
seem to rule out the possibility that the fusion activation
of coronavirus spikes, not just of SARS-CoV but possibly even
of CoV carrying furin-cleaved S proteins, might still be triggered
at a very late stage by the proteolytic liberation of the fusion
peptide. This feature sets the CoV fusion proteins distinctively
apart from the other class I fusion proteins, which generate
a fusion peptide at the N terminus of their fusion subunit.
It is, however, consistent with the specific properties of the
CoV fusion peptides, which share remarkable similarities with
the internally located fusion peptides of class II fusion proteins
(
2).
Cathepsin L cleavage of the SARS-CoV spike protein supposedly occurs at a post-receptor-binding stage during virus entry. It would thus be conceivable that receptor interaction uncovers additional, previously cryptic cathepsin L target sites. However, we did not observe any difference between cathepsin L proteolysis of SARS-CoV spikes bound to the ACE2 receptor and that of unbound spikes (data not shown). This is in agreement with recent cryoelectron microscopic findings showing that ACE2 receptor interaction induces just a minimal conformational change in the SARS-CoV spike (1). Cleavage of the SARS-CoV spike protein brings the protein to a metastable state, thereby allowing the structural transitions that are instrumental to the membrane fusion process. It has been reported that exogenous trypsin cleavage of trimeric spikes at the S1/S2 border resulted in a gradual separation of S1 from the S2 subunit, which in turn resulted in S2 aggregation. The S2 aggregates appeared as rosettes under the electron microscope (8), reminiscent of the postfusion structures of the influenzavirus and paramyxovirus fusion proteins, which form rosettes via interaction of their fusion peptides (4, 6, 15). We therefore favor the hypothesis that cathepsin L cleavage of the SARS-CoV spike protein during cell entry is an essential trigger for the dissociation of S1 from the trimer, with the consequent release of the (internal) fusion peptide toward the target membrane (16). Such a scenario might explain the results of earlier attempts to enhance (pseudo)virion infectivity by exogenous spike cleavage or by engineering a furin cleavage site in the S protein, which may have failed due to premature loss of S1 (8, 12).
The S protein in the SARS-CoV spike apparently exposes a protease-accessible loop between the S1 and S2 subunits that can be targeted by different enzymes, such as cathepsin L, trypsin, and, under physiological conditions, local enzymes such as elastase. Consistent with the presence of such a loop, the syncytium-inducing capacity of expressed SARS-CoV S protein was dramatically enhanced after the introduction of a functional furin cleavage site in the S1/S2 junction region (8, 14). No such loop has been detected yet in spikes of HCoV-NL63 or of most other subgroup 1 coronaviruses. The resistance of the HCoV-NL63 spike ectodomain to cleavage by cathepsin L and trypsin that we observed here is in agreement with our inability to inhibit infection with HCoV-NL63 or an NL63 spike protein-pseudotyped retrovirus by using a broad spectrum of protease inhibitors (10). It is conceivable that during its low-pH-independent cell entry, HCoV-NL63 uses an alternative, possibly nonproteolytic way to activate the fusion function.

ACKNOWLEDGMENTS
We thank B. Tummers and V. Bourgonje for technical assistance
in the beginning and throughout the project, respectively. R.
Wubbolts and A. M. de Graaf are gratefully acknowledged for
assistance with the confocal laser scanning microscope. We thank
H. Deng (Department of Cell Biology and Genetics, College of
Life Sciences, Peking University, Beijing, China) and H. Choe
(Pulmonary Division, Children's Hospital, Harvard Medical School,
Boston, MA) for providing the plasmids containing the human
codon-optimized SARS-CoV and HCoV-NL63 spike genes, respectively,
and we thank L. A. Babiuk (Vaccine and Infectious Disease Organization,
University of Saskatchewan, Saskatoon, Canada) for providing
the polyclonal peptide sera directed to the SARS-CoV S glycoprotein.
We thank R. A. P. Romijn (U-Protein Express B.V., Utrecht, The
Netherlands) for assistance with the purification and analyses
of the spike ectodomains.
B.J.B. is supported by VENI grant 016.062.027 from The Netherlands Organization for Scientific Research (NWO).

FOOTNOTES
* Corresponding author. Mailing address: Virology Division, Department of Infectious Diseases and Immunology, Utrecht University, Faculty of Veterinary Medicine, Yalelaan 1, 3584 CL Utrecht, P.O. Box 80.165, 3508 TD Utrecht, The Netherlands. Phone: 31-30-2532462. Fax: 31-30-2536723. E-mail:
p.rottier{at}uu.nl 
Published ahead of print on 18 June 2008. 

REFERENCES
1 - Beniac, D. R., S. L. Devarennes, A. Andonov, R. He, and T. F. Booth. 2007. Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion. PLoS ONE 2:e1082.[CrossRef]
2 - Bosch, B. J., B. E. Martina, R. Van Der Zee, J. Lepault, B. J. Haijema, C. Versluis, A. J. Heck, R. De Groot, A. D. Osterhaus, and P. J. Rottier. 2004. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl. Acad. Sci. USA 101:8455-8460.[Abstract/Free Full Text]
3 - Bosch, B. J., R. van der Zee, C. A. de Haan, and P. J. Rottier. 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J. Virol. 77:8801-8811.[Abstract/Free Full Text]
4 - Calder, L. J., L. Gonzalez-Reyes, B. Garcia-Barreno, S. A. Wharton, J. J. Skehel, D. C. Wiley, and J. A. Melero. 2000. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:122-131.[CrossRef][Medline]
5 - Chambers, P., C. R. Pringle, and A. J. Easton. 1990. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 71:3075-3080.[Abstract/Free Full Text]
6 - Connolly, S. A., G. P. Leser, H. S. Yin, T. S. Jardetzky, and R. A. Lamb. 2006. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc. Natl. Acad. Sci. USA 103:17903-17908.[Abstract/Free Full Text]
7 - de Haan, C. A., K. Stadler, G. J. Godeke, B. J. Bosch, and P. J. Rottier. 2004. Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion. J. Virol. 78:6048-6054.[Abstract/Free Full Text]
8 - Follis, K. E., J. York, and J. H. Nunberg. 2006. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. Virology 350:358-369.[CrossRef][Medline]
9 - Honey, K., and A. Y. Rudensky. 2003. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3:472-482.[CrossRef][Medline]
10 - Huang, I. C., B. J. Bosch, F. Li, W. Li, K. H. Lee, S. Ghiran, N. Vasilieva, T. S. Dermody, S. C. Harrison, P. R. Dormitzer, M. Farzan, P. J. Rottier, and H. Choe. 2006. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 281:3198-3203.[Abstract/Free Full Text]
11 - Li, F., M. Berardi, W. Li, M. Farzan, P. R. Dormitzer, and S. C. Harrison. 2006. Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. J. Virol. 80:6794-6800.[Abstract/Free Full Text]
12 - Matsuyama, S., M. Ujike, S. Morikawa, M. Tashiro, and F. Taguchi. 2005. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc. Natl. Acad. Sci. USA 102:12543-12547.[Abstract/Free Full Text]
13 - Nie, Y., P. Wang, X. Shi, G. Wang, J. Chen, A. Zheng, W. Wang, Z. Wang, X. Qu, M. Luo, L. Tan, X. Song, X. Yin, M. Ding, and H. Deng. 2004. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem. Biophys. Res. Commun. 321:994-1000.[CrossRef][Medline]
14 - Qiu, Z., S. T. Hingley, G. Simmons, C. Yu, J. Das Sarma, P. Bates, and S. R. Weiss. 2006. Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J. Virol. 80:5768-5776.[Abstract/Free Full Text]
15 - Ruigrok, R. W., A. Aitken, L. J. Calder, S. R. Martin, J. J. Skehel, S. A. Wharton, W. Weis, and D. C. Wiley. 1988. Studies on the structure of the influenza virus haemagglutinin at the pH of membrane fusion. J. Gen. Virol. 69:2785-2795.[Abstract/Free Full Text]
16 - Simmons, G., D. N. Gosalia, A. J. Rennekamp, J. D. Reeves, S. L. Diamond, and P. Bates. 2005. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA 102:11876-11881.[Abstract/Free Full Text]
17 - Simmons, G., J. D. Reeves, A. J. Rennekamp, S. M. Amberg, A. J. Piefer, and P. Bates. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. USA 101:4240-4245.[Abstract/Free Full Text]
18 - Turk, B., D. Turk, and V. Turk. 2000. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477:98-111.[CrossRef][Medline]
Journal of Virology, September 2008, p. 8887-8890, Vol. 82, No. 17
0022-538X/08/$08.00+0 doi:10.1128/JVI.00415-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Matsuyama, S., Taguchi, F.
(2009). Two-Step Conformational Changes in a Coronavirus Envelope Glycoprotein Mediated by Receptor Binding and Proteolysis. J. Virol.
83: 11133-11141
[Abstract]
[Full Text]
-
Yamada, Y., Liu, D. X.
(2009). Proteolytic Activation of the Spike Protein at a Novel RRRR/S Motif Is Implicated in Furin-Dependent Entry, Syncytium Formation, and Infectivity of Coronavirus Infectious Bronchitis Virus in Cultured Cells. J. Virol.
83: 8744-8758
[Abstract]
[Full Text]
-
Schornberg, K. L., Shoemaker, C. J., Dube, D., Abshire, M. Y., Delos, S. E., Bouton, A. H., White, J. M.
(2009). {alpha}5{beta}1-Integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc. Natl. Acad. Sci. USA
106: 8003-8008
[Abstract]
[Full Text]
-
Belouzard, S., Chu, V. C., Whittaker, G. R.
(2009). Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. USA
106: 5871-5876
[Abstract]
[Full Text]
-
Kawase, M., Shirato, K., Matsuyama, S., Taguchi, F.
(2009). Protease-Mediated Entry via the Endosome of Human Coronavirus 229E. J. Virol.
83: 712-721
[Abstract]
[Full Text]
-
Watanabe, R., Matsuyama, S., Shirato, K., Maejima, M., Fukushi, S., Morikawa, S., Taguchi, F.
(2008). Entry from the Cell Surface of Severe Acute Respiratory Syndrome Coronavirus with Cleaved S Protein as Revealed by Pseudotype Virus Bearing Cleaved S Protein. J. Virol.
82: 11985-11991
[Abstract]
[Full Text]